Lee, Jangsoon
Lim, Bora
Pearson, Troy
Choi, Kuicheon
Fuson, Jon A.
Bartholomeusz, Chandra
Paradiso, Linda J.
Myers, Thomas
Tripathy, Debu
Ueno, Naoto T. http://orcid.org/0000-0002-0166-7275
Funding for this research was provided by:
Foundation for the National Institutes of Health (CA123318, P30CA016672)
Spirita Oncology
Article History
Received: 20 November 2018
Accepted: 9 February 2019
First Online: 2 March 2019
Change Date: 15 April 2019
Change Type: Correction
Change Details: Unfortunately in the original publication of the article, the author’s funding support has been mentioned incorrectly. The correct funding statement should read as “This work was supported by the Morgan Welch Inflammatory Breast Cancer Research Program, the State of Texas Rare and Aggressive Breast Cancer Research Program, MD Anderson’s Cancer Center Support Grant (P30CA016672, used the Characterized Cell Line Core Facility and Flow Cytometry and Cellular Imaging Facility), and Spirita Oncology, LLC.”The first affiliations was incorrect in the original article. The correct information is given below.
Compliance with ethical standards
:
: Naoto T. Ueno has a research agreement with Spirita Oncology, LLC. Linda J. Paradiso and Thomas Myers are employees of Spirita Oncology, LLC. All other authors declare no potential conflicts of interest.
: Animal studies and procedures were approved by The University of Texas MD Anderson Cancer Center Animal Care and Use Committee. Protocol #: 00000968-RN02 (approval date 5/1/2015, expiration date 4/22/2021).
: This article does not contain any studies with human participants by any of the authors.